Inflammatory bowel disease is a chronic relapsing immune-mediated disease of the intestinal tract. Although its prevalence is investigated to be lower in Asia than in Western countries, the rapid increase in the incidence rate of inflammatory bowel disease has drawn attention to the etiology of inflammatory bowel disease, including genetic susceptibility and environmental factors. Specifically, recent studies concerning dietary treatments and intestinal microbiota suggest that these factors may interact with the immune system, and the imbalance of this relationship may lead to the immune dysregulation in inflammatory bowel disease. The changes in diet or alteration in the composition of intestinal microbiota may be associated with the increasing incidence of inflammatory bowel disease in Asia. Here, we aim to review the recent studies on the role of the diet and intestinal microbiota in inflammatory bowel disease pathogenesis and the results of the investigations performed to modulate these factors. A c c e p t e d A r t i c l e Introduction Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is an immune-mediated, chronic relapsing, inflammatory condition that mainly affects the gastrointestinal tract. The incidence and prevalence of IBD is increasing globally. Although reportedly higher in Western countries, a similar trend is now being observed in Asia as well. The prevalence of CD and UC in Canada in 2008 was 255.2 per 100,000 (95% confidence interval (CI), 252.4-258.0) and 259.7 per 100,000 (95% CI, 256.9-262.5), respectively, and the prevalence of CD and UC in the commercially-insured US adult population during 2008-2009 was 241.3 (95% CI, 238.1-244.5) and 263.0 (95% CI, 259.7-266.4) per 100,000, respectively.(1, 2) In
Westernized environment. Although genetic factors appear to play an important role in the pathogenesis of IBD, as shown in Swedish cohort studies on identical twins, environmental changes over the past few decades have been one of the important factors in raising the incidence of IBD in Asia. (3, 8, 9) This is supported by the higher incidence of illness among immigrants who migrate from countries with low incidence to Western countries. (10) The environmental changes and subsequent alterations of intestinal microbiota are regarded to be important in increased prevalence of IBD in Asia. Therapeutic approaches involving these factors show efficacy in recent studies also support this proposition. (11) (12) (13) (14) (15) (16) (17) In this review, we will discuss the environmental, nutritional and microbial factors that attribute to the pathogenesis of IBD as well as therapeutic approaches by modulating these factors. These varied evidences suggest that the dietary pattern influences the composition of the intestinal microbiota and, through this indirect mechanism, diet can determine subsequent intestinal inflammation ( Figure 1 ).
Diet as an environmental factor

Environmental modification as a treatment
Dietary modification.
Exclusive enteral nutrition (EEN) is the only evidence-based dietary treatment of IBD. EEN involves a completely liquid diet without any normal dietary components for a certain period of time. It is used as a therapeutic method to induce remission in pediatric patients with active CD. (45) 
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According to a meta-analysis, EEN is as effective as corticosteroids in inducing remission in pediatric CD patients. This is true not only for newly diagnosed CD but for relapsed cases as well (OR: 0.76, 95% CI: 0.29-1.98). Furthermore, EEN was found to be more effective than corticosteroids with respect to mucosal healing (OR: 4.5, 95% CI: 1.64-12.32). 
Behalf of the Porto Inflammatory Bowel Disease Group of the ESPGHAN also stated that "elimination or restrictive diet in children/adolescents with IBD should not be recommended unless potential benefits outweigh potential risks of the diet."(61)
Use of probiotics and prebiotics in the treatment of IBD
Ever since intestinal microorganisms were known to attribute to the pathogenesis of IBD, efforts have been made to restore this altered microbial composition. Administration of probiotics and prebiotics as a mean of IBD treatment has been investigated with inconsistent results. (21) Probiotics are defined as live microorganisms that are, when ingested in adequate amounts, beneficial to the health of host. As derived from commensal microbiota, they mimic the homeostatic effect of intestinal microbiota in healthy condition. They affect the mucosal immune system by balancing pro-and anti-inflammatory components, alter the microbial composition by inhibiting the pathogenic bacteria, and enhance the barrier function. (62) (63) (64) (65) Although many probiotics demonstrated limited efficacy in UC, the probiotic cocktail VSL#3
and Escherichia coli Nissle 1917 showed to reduce active inflammation in many studies.(66-69) They were associated with increased mucosal regulatory T cells, reduced proinflammatory cytokines, increased microbial diversity, and restoration of barrier integrity.
However, they did not show statistically significant impact in treating CD. (70, 71) In addition, several microbes such as Faecalibacterium prausnitzii and Bacteroides fragilis have been studied for their therapeutic potential as they seem to be beneficial in reducing the severity of colitis in many mouse models. (72) (73) (74) As shown above, some taxa seem to be associated with the disease course of IBD through the interaction with the immune system.(38-40) However, changes of specific microbiota that A c c e p t e d A r t i c l e increase risk of IBD are not completely clear. Therefore, it is important not only to manipulate specific microbiota but also to enhance the overall environment of beneficial microorganisms. Moreover, the fact that dietary modification affects the disease course of IBD also suggests the significance of prebiotics as nutrient source of microbiota.
Prebiotics are non-digestible food components fermented by microbiota to elicit advantages to the host. By providing essential food to the microbiota, prebiotics can modify the gut microbial composition and subsequent metabolites. For instance, oligosaccharide and fibers induce proliferation of short chain fatty acid producing bacteria, such as Bacteroides genus, to improve the severity of colitis in IBD. (75, 76) In many in vitro and animal research also confirmed that providing prebiotics help to alleviate the severity of colitis by an alteration of microbial composition, the production of short chain fatty acids such as butyrate, and balances in pro-and anti-inflammatory cytokines. (77) (78) (79) (80) There are several human studies conducted to confirm the efficacy of prebiotics in IBD subject are tremendously heterogeneous in the study design, mode of administration, and used probiotics or prebiotics to lead to a firm conclusion. Therefore, well-designed further study in larger population is needed in order to find which probiotics or prebiotics are effective in treatment of IBD.
Intestinal microbiota modification as a treatment; fecal microbiota transplantation
Another attempt to modulate intestinal microbiota is fecal microbiota transplantation (FMT).
FMT is regarded as the most direct method to manipulate the intestinal microbiota profile and there is much on-going research regarding FMT as a potential treatment for IBD.
As the first case of FMT in pseudomembranous colitis was reported several decades ago, FMT has been well studied and proven to be an effective and safe treatment in refractory or 
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analysis of four RCTs also showed significant benefit in clinical remission (pooled OR: 2.89, 95% CI: 1.36-6.13, p = 0.006).(88) Consequent to these studies, the American Gastroenterological Association has stated the efficacy of FMT in induction of remission in mild-moderate UC. (89) In pediatric patients, there is no published RCT, but six cohort studies assessing 34 UC patients and two cohort studies assessing 13 CD patients showed a pooled estimated clinical remission rate of 23% (95% CI: 7-51) in UC and 54% (95% CI: 28-78) in CD patients. (88) The clinical trials and their results of FMT in pediatric IBD patients are summarized in Table   2 . (90-100) FMT has been considered a relatively safe treatment modality with a low rate of adverse events, when there was a thorough investigation of donor fecal material. Any reported side effects were mild and self-limiting.(101) Although serious adverse events (SAEs), such as flaring up of the disease, were reported in several studies, recent meta-analysis showed no significant difference between the FMT and the control groups with respect to SAEs. The pooled rate of SAEs was 7.1% in the FMT group versus 5.1% in the control group with no significant difference (risk ratio adverse event: 1.40, 95% CI: 0.55-3.58, p = 0.49). (102) FMT can be considered a relatively safe and effective treatment option in IBD by modulating intestinal microbiota. However, a number of factors affecting the outcome and efficacy of FMT need to be determined, including pretreatment before FMT, dosage and frequency, preparation of donor stools, and routes of administration. Further studies are needed to have a better understanding of FMT and to provide optimal FMT in IBD.(12)
Conclusion
Numerous environmental factors can attribute to the increasing incidence of IBD. Of these, Both the genetic susceptibility and diet can account for the incidence of inflammatory bowel disease and microbial composition. Inflammatory bowel disease itself and disease severity are also responsible for the microbial composition, and conversely dysbiosis is also thought to affect inflammatory bowel disease.
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